Coronavirus Update: After UK Nod, New Forecast Makes Pfizer Vaccine The Leader
Plus Russia Extends India Alliances
After its historic first emergency approval, analysts at Bernstein has upgraded predictions for Pfizer/BioNTech's COVID-19 vaccine in 2021 and beyond.
You may also be interested in...
Our updated graphic tracker of key developments from the leading vaccine candidates.
The UK's MHRA has granted an emergency authorization to the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.